Enhertu Approved in the US as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer

Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy 6 August 2022 --...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news